Andrew Saik, Chief Financial Officer at VYNE Therapeutics Inc. (VYNE), bought 40,000 shares at $1.46 ($58K) on 2020-09-08, disclosed to the SEC on 2020-09-08.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Clearly above the average filing.
| Filing → |
| ARVN | SELL | 2026-02-18 | $61K | — | Filing → |
| ARVN | SELL | 2025-06-24 | $43K | — | Filing → |